Held on 27–28 May 2026, the event focused on practical discussion across biologics, biosimilars, and advanced molecules. We were pleased to welcome all confirmed attendees across the full two-day program.
The scientific program covered a broad range of topics shaping the future of advanced therapeutics development, including:
- sustainable biosimilar development in Europe,
- tailored clinical and regulatory approaches,
- weight of evidence strategies for complex molecules,
- FDA registration opportunities for European developers,
- recombinant bacterial endotoxin testing,
- patient safety,
- trustworthy clinical data,
- and development, manufacturing, and bioanalytical challenges in ADC programs.
Beyond the formal scientific sessions, the forum continued through coffee break discussions, roundtables, the Conscio Prague site visit, and networking moments throughout both days.
We would like to sincerely thank all speakers, partners, and attendees for their expertise, engagement, and contribution throughout the event.
Following the success of this year’s Prague edition, Conscio Group and partners are already preparing the next Biologics & Advanced Molecules Science Days in Prague for 2027.
The discussion will also continue earlier, with the traditional Science Day at the Conscio Group Headquarters in Munich in early October, focusing primarily on innovations in formulation development and in-vitro bioequivalence studies.
Follow our website and LinkedIn for updates, or contact us directly if you would like to take part.
Would you like to know more? Contact our team.
